Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chimeric dengue serotype · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Received monovalent Vero dengue vaccine in Study DIV12 |
| 2 | EXPERIMENTAL | Received Yellow fever vaccine in Study DIV12 |
| 3 | EXPERIMENTAL | Flavivirus-naive subjects |
| Name | Type | Description |
|---|---|---|
| Chimeric dengue serotype (1, 2, 3, 4) | BIOLOGICAL | 0.5 mL, Subcutaneous, 1 dose |
Inclusion Criteria : * Aged 18 to 40 years on the day of inclusion. * Informed consent form signed. * For a woman, inability to bear a child or negative serum pregnancy test. * Completed the one-year follow-up of Study DIV12. * Able to attend all scheduled visits and to comply with all trial proced...
Top 2 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Qdenga |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
Chimeric dengue serotype is being developed for the prevention of dengue, including dengue fever, dengue hemorrhagic fever, and dengue virus infection. It is a vaccine candidate studied in healthy adult volunteers. It is not approved and remains in clinical development.
Sanofi is developing Chimeric dengue serotype. The company trades under the ticker SNY. The candidate was studied in a Phase 2 trial conducted in Australia.
Chimeric dengue serotype is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. It is an investigational product and has not been approved by the FDA.
Chimeric dengue serotype was evaluated in a single completed Phase 2 trial, NCT00730288, titled Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects. The trial enrolled 35 healthy adult volunteers in Australia and used a controlled, randomized design without double blinding.
Yes. Chimeric dengue serotype is also known as Chimeric dengue serotype (1, 2, 3, 4). The parenthetical numbers refer to the four dengue virus serotypes covered by the tetravalent vaccine candidate developed by Sanofi.